[{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Symbiosis Pharmaceutical Services \/ SymBiosis","highestDevelopmentStatusID":"10","companyTruncated":"Symbiosis Pharmaceutical Services \/ SymBiosis"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"Enterome","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"EO2401","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Symbiosis Pharmaceutical Services","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Symbiosis Pharmaceutical Services \/ SymBiosis, LLC","highestDevelopmentStatusID":"7","companyTruncated":"Symbiosis Pharmaceutical Services \/ SymBiosis, LLC"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Symbiosis Pharmaceutical Services \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Symbiosis Pharmaceutical Services \/ AstraZeneca"}]

Find Clinical Drug Pipeline Developments & Deals by Symbiosis Pharmaceutical Services

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Financing will be used to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.

                          Brand Name : EO2401

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 25, 2020

                          Lead Product(s) : EO2401

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Enterome

                          Deal Size : $52.6 Million

                          Deal Type : Financing

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.

                          Brand Name : AZD1222

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 22, 2020

                          Lead Product(s) : AZD1222

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 05, 2020

                          Lead Product(s) : MaaT013

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : MaaT Pharma

                          Deal Size : $19.5 million

                          Deal Type : Series B Financing

                          blank